All Stories

  1. Insulin edema in slowly progressive type 1 diabetes: improvement following adjustment of insulin therapy

    Article • Diabetology International, December 2025, Springer Science + Business Media

    Dr Daisuke Yabe

  2. Improvement of Symptoms in a Patient With Glycogen Storage Disease Through Nutritional Guidance and Exercise Therapy

    Article • JCEM Case Reports, September 2025, Endocrine Society

    Dr Daisuke Yabe

  3. Response to commentary on ‘A prediction model for diabetes complications using the Kokuho Database and its application to public health services in Japan’

    Article • Journal of Diabetes Investigation, September 2025, Wiley

    Dr Daisuke Yabe

  4. Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐regression analysis incorporating ...

    Article • Diabetes Obesity and Metabolism, September 2025, Wiley

    Dr Daisuke Yabe

  5. Heterogeneous cardiovascular effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a causal forest and target trial emulation study

    Article • European Journal of Preventive Cardiology, September 2025, Oxford University Press (OUP)

    Dr Daisuke Yabe

  6. Insulinoma diagnosis and characterization with intratumoral heterogeneity employing [18F]FB(ePEG12)12-exendin-4 PET/MRI

    Article • European Journal of Pediatrics, August 2025, Springer Science + Business Media

    Dr Daisuke Yabe

  7. A multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice ( PIONEER REAL Japan): Subgroup analyses

    Article • Journal of Diabetes Investigation, July 2025, Wiley

    Dr Daisuke Yabe

  8. Accelerating innovation and ensuring the thoughtful withdrawal of lifeline medicines for people living with diabetes in Asia

    Article • Journal of Diabetes Investigation, May 2025, Wiley

    Dr Daisuke Yabe

  9. Evolving incretin-based therapies in Japan: optimizing treatment strategies for diverse clinical and socioeconomical profiles in type 2 diabetes

    Article • Diabetology International, May 2025, Springer Science + Business Media

    Dr Daisuke Yabe

  10. Correction: Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial

    Article • Diabetologia, May 2025, Springer Science + Business Media

    Dr Daisuke Yabe

  11. Depression risk associated with spouses’ diabetes and cardiovascular events: a nationwide cohort study

    Article • American Journal of Epidemiology, April 2025, Oxford University Press (OUP)

    Dr Daisuke Yabe

  12. A prediction model for diabetes complications using the Kokuho Database and its application to public health services in Japan

    Article • Journal of Diabetes Investigation, April 2025, Wiley

    Dr Daisuke Yabe

  13. Voltage-gated calcium channel α2δ-1 subunit is involved in the regulation of glucose-stimulated GLP-1 secretion in mice

    Article • AJP Gastrointestinal and Liver Physiology, March 2025, American Physiological Society

    Dr Daisuke Yabe

  14. Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial

    Article • Diabetologia, January 2025, Springer Science + Business Media

    Dr Daisuke Yabe

  15. Toward a cure for diabetes: iPSC and ESC‐derived islet cell transplantation trials

    Article • Journal of Diabetes Investigation, November 2024, Wiley

    Dr Daisuke Yabe

  16. The Ulaanbaatar agreement: Revising diabetes terminology in Asia to combat stigma

    Article • Journal of Diabetes Investigation, October 2024, Wiley

    Dr Daisuke Yabe

  17. Quality of Life in Japanese People with Type 2 Diabetes Switching from Multiple Daily Insulin Injections to Once-Daily iGlarLixi: SIMPLIFY Japan

    Article • Diabetes Therapy, September 2024, Springer Science + Business Media

    Dr Daisuke Yabe

  18. PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice

    Article • Journal of Diabetes Investigation, August 2024, Wiley

    Dr Daisuke Yabe

  19. Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice

    Article • Journal of Diabetes Investigation, August 2024, Wiley

    Dr Daisuke Yabe

  20. Sporadic Parathyroid Carcinoma Treated With Lenvatinib, Exhibiting a Novel Somatic MEN1 Mutation

    Article • JCEM Case Reports, July 2024, Endocrine Society

    Dr Daisuke Yabe

  21. A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes – 2nd edition (English version)

    Article • Journal of Diabetes Investigation, July 2024, Wiley

    Dr Daisuke Yabe

  22. A Study on the Compatibility of a Food-Recording Application with Questionnaire-Based Methods in Healthy Japanese Individuals

    Article • Nutrients, June 2024, MDPI AG

    Dr Daisuke Yabe

  23. Obsessive‐compulsive disorder as an initial manifestation of anti‐glutamic acid decarboxylase antibody‐associated encephalitis

    Article • Neurology and Clinical Neuroscience, May 2024, Wiley

    Dr Daisuke Yabe

  24. PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan

    Article • Journal of Diabetes Investigation, May 2024, Wiley

    Dr Daisuke Yabe

  25. Japanese 17q12 Deletion Syndrome with Complex Clinical Manifestations

    Article • Internal Medicine, March 2024, Japanese Society of Internal Medicine

    Dr Daisuke Yabe

  26. Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan

    Article • Diabetes Therapy, February 2024, Springer Science + Business Media

    Dr Daisuke Yabe

  27. Visceral Adipose Tissue Quality and its Impact on Metabolic Health

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2024, Endocrine Society

    Dr Daisuke Yabe

  28. Primary aldosteronism patients with previous cardiovascular and cerebrovascular events have high aldosterone responsiveness to ACTH stimulation

    Article • Endocrine Journal, January 2024, Japan Endocrine Society

    Dr Daisuke Yabe

  29. [<sup>18</sup>F]FB(ePEG12)12-exendin-4 noninvasive imaging of insulinoma negative for insulin immunostaining on specimen from endoscopic ultrasonography-guided fine needle aspiration: a case report with review of literature

    Article • Endocrine Journal, January 2024, Japan Endocrine Society

    Dr Daisuke Yabe

  30. Lifestyle factors associated with a rapid decline in the estimated glomerular filtration rate over two years in older adults with type 2 diabetes–Evidence from a large national database in Japan

    Article • PLOS One, December 2023, PLOS

    Dr Daisuke Yabe

  31. Front Cover

    Article • Diabetes Obesity and Metabolism, November 2023, Wiley

    Dr Daisuke Yabe

  32. Glucokinase Variant Proteins Are Resistant to Fasting-Induced Uridine Diphosphate Glucose-Dependent Degradation in Maturity-Onset Diabetes of the Young Type 2 Patients

    Article • International Journal of Molecular Sciences, October 2023, MDPI AG

    Dr Daisuke Yabe

  33. Long‐term safety and efficacy of SGLT2 inhibitor use in older east Asians with type 2 diabetes

    Article • Journal of Diabetes Investigation, October 2023, Wiley

    Dr Daisuke Yabe

  34. Dietary and Nutritional Guidelines for People with Diabetes

    Article • Nutrients, October 2023, MDPI AG

    Dr Daisuke Yabe

  35. Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice

    Article • Nutrients, August 2023, MDPI AG

    Dr Daisuke Yabe

  36. Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY)

    Article • Diabetes Obesity and Metabolism, August 2023, Wiley

    Dr Daisuke Yabe

  37. Effect of Roxadustat on Thyroid Function in Patients With Renal Anemia

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2023, Endocrine Society

    Dr Daisuke Yabe

  38. Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls

    Article • Journal of Diabetes Investigation, June 2023, Wiley

    Dr Daisuke Yabe

  39. Effectiveness of countermeasure for polypharmacy by multidisciplinary team review in patients with diabetes mellitus

    Article • Journal of Diabetes Investigation, June 2023, Wiley

    Dr Daisuke Yabe

  40. Device-supported automated basal insulin titration in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

    Article • The Lancet Regional Health - Western Pacific, June 2023, Elsevier

    Dr Daisuke Yabe

  41. Efficacy and Safety of 6-Month High Dietary Protein Intake in Hospitalized Adults Aged 75 or Older at Nutritional Risk: An Exploratory, Randomized, Controlled Study

    Article • Nutrients, April 2023, MDPI AG

    Dr Daisuke Yabe

  42. Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta‐analysis

    Article • Journal of Diabetes, April 2023, Wiley

    Dr Daisuke Yabe

  43. Effect of the Diabetic Nephropathy Aggravation Prevention Program on medical visit behavior in individuals under the municipal national health insurance

    Article • Journal of Diabetes Investigation, March 2023, Wiley

    Dr Daisuke Yabe

  44. Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study

    Article • Diabetes Therapy, February 2023, Springer Science + Business Media

    Dr Daisuke Yabe

  45. Erdheim-Chester Disease With BRAF V600E Mutation and Central Diabetes Insipidus Successfully Treated With Glucocorticoid

    Article • JCEM Case Reports, February 2023, Endocrine Society

    Dr Daisuke Yabe

  46. Current status of the rapid decline in renal function due to diabetes mellitus and its associated factors: analysis using the National Database of Health Checkups in Japan

    Article • Hypertension Research, February 2023, Springer Science + Business Media

    Dr Daisuke Yabe

  47. Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study

    Article • Journal of Diabetes Investigation, January 2023, Wiley

    Dr Daisuke Yabe

  48. Two cases of systemic lupus erythematosus after administration of severe acute respiratory syndrome coronavirus 2 vaccine

    Article • Modern Rheumatology Case Reports, January 2023, Oxford University Press (OUP)

    Dr Daisuke Yabe

  49. Editorial: Advances in the research of diabetic nephropathy, volume II

    Article • Frontiers in Endocrinology, January 2023, Frontiers

    Dr Daisuke Yabe

  50. Editorial: Advances in the research of diabetic nephropathy

    Article • Frontiers in Endocrinology, January 2023, Frontiers

    Dr Daisuke Yabe

  51. Increased expression of glucagon-like peptide-1 and cystic fibrosis transmembrane conductance regulator in the ileum and colon in mouse treated with metformin

    Article • Endocrine Journal, January 2023, Japan Endocrine Society

    Dr Daisuke Yabe

  52. Current understanding of imeglimin action on pancreatic β‐cells: Involvement of mitochondria and endoplasmic reticulum homeostasis

    Article • Journal of Diabetes Investigation, December 2022, Wiley

    Dr Daisuke Yabe

  53. Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study

    Article • Diabetes Therapy, November 2022, Springer Science + Business Media

    Dr Daisuke Yabe

  54. Cover Image, Volume 24, Issue 12

    Article • Diabetes Obesity and Metabolism, October 2022, Wiley

    Jun Wada, Dr Daisuke Yabe

  55. An analysis of intestinal morphology and incretin-producing cells using tissue optical clearing and 3-D imaging

    Article • Scientific Reports, October 2022, Springer Science + Business Media

    Dr Daisuke Yabe

  56. Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment

    Article • Internal Medicine, September 2022, Japanese Society of Internal Medicine

    Dr Daisuke Yabe

  57. Advances in insulin therapy from discovery to β‐cell replacement

    Article • Journal of Diabetes Investigation, September 2022, Wiley

    Dr Daisuke Yabe

  58. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan

    Article • Diabetes Obesity and Metabolism, August 2022, Wiley

    Jun Wada, Dr Daisuke Yabe

  59. d-Allulose Inhibits Ghrelin-Responsive, Glucose-Sensitive and Neuropeptide Y Neurons in the Arcuate Nucleus and Central Injection Suppresses Appetite-Associated Food Intake in Mice

    Article • Nutrients, July 2022, MDPI AG

    Dr Daisuke Yabe

  60. Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient

    Article • Internal Medicine, May 2022, Japanese Society of Internal Medicine

    Dr Daisuke Yabe

  61. Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study

    Article • Expert Opinion on Drug Safety, May 2022, Taylor & Francis

    Dr Daisuke Yabe

  62. Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index

    Article • Journal of Diabetes Investigation, March 2022, Wiley

    Dr Daisuke Yabe

  63. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials

    Article • Journal of Diabetes Investigation, March 2022, Wiley

    Dr Daisuke Yabe

  64. Healthcare resource utilization in patients treated with empagliflozin in East Asia

    Article • Journal of Diabetes Investigation, January 2022, Wiley

    Dr Daisuke Yabe

  65. Unmet needs in current clinical practice for insulinoma: Lessons from nationwide studies in Japan

    Article • Journal of Diabetes Investigation, December 2021, Wiley

    Dr Daisuke Yabe

  66. Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials

    Article • Expert Opinion on Drug Safety, November 2021, Taylor & Francis

    Dr Daisuke Yabe

  67. Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials

    Article • Diabetes Obesity and Metabolism, November 2021, Wiley

    Dr Daisuke Yabe

  68. Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP‐O2 trial

    Article • Diabetes Obesity and Metabolism, September 2021, Wiley

    Dr Daisuke Yabe

  69. Effects of physician’s diabetes self‐management education using Japan Association of Diabetes Education and Care Diabetes Education Card System Program and a self‐monitoring of blood glucose readings analyzer in individuals with type 2 diabetes: An exp...

    Article • Journal of Diabetes Investigation, July 2021, Wiley

    Dr Daisuke Yabe

  70. Voxel‐based specific regional analysis system for Alzheimer’s disease utility as a screening tool for unrecognized cognitive dysfunction of elderly patients in diabetes outpatient clinics: Multicenter retrospective exploratory study

    Article • Journal of Diabetes Investigation, July 2021, Wiley

    Dr Daisuke Yabe

  71. iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial

    Article • Journal of Diabetes Investigation, June 2021, Wiley

    Dr Daisuke Yabe

  72. Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

    Article • Journal of Diabetes Investigation, June 2021, Wiley

    Dr Daisuke Yabe

  73. Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?

    Article • The Journal of Clinical Endocrinology & Metabolism, May 2021, Endocrine Society

    Dr Daisuke Yabe

  74. Carbonic anhydrase 8 (CAR8) negatively regulates GLP-1 secretion from enteroendocrine cells in response to long-chain fatty acids

    Article • AJP Gastrointestinal and Liver Physiology, April 2021, American Physiological Society

    Dr Daisuke Yabe

  75. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 dia...

    Article • BMJ Open, April 2021, BMJ

    Dr Daisuke Yabe

  76. Effect of hypertriglyceridemia in dyslipidemia‐induced impaired glucose tolerance and sex differences in dietary features associated with hypertriglyceridemia among the Japanese population: The Gifu Diabetes Study

    Article • Journal of Diabetes Investigation, October 2020, Wiley

    Dr Daisuke Yabe

  77. The Asian Association for the Study of Diabetes: The first 10 years and the next 10 years

    Article • Journal of Diabetes Investigation, August 2020, Wiley

    Dr Daisuke Yabe

  78. Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?

    Article • Journal of Diabetes Investigation, June 2020, Wiley

    Dr Daisuke Yabe

  79. SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes

    Article • Internal Medicine, June 2020, Japanese Society of Internal Medicine

    Dr Daisuke Yabe

  80. The Role of Metagenomics in Precision Nutrition

    Article • Nutrients, June 2020, MDPI AG

    Dr Daisuke Yabe

  81. Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects

    Article • Journal of Diabetes Investigation, June 2020, Wiley

    Dr Daisuke Yabe

  82. Tumor‐like features of gene expression and metabolic profiles in enlarged pancreatic islets are associated with impaired incretin‐induced insulin secretion in obese diabetes: A study of Zucker fatty diabetes mellitus rat

    Article • Journal of Diabetes Investigation, May 2020, Wiley

    Dr Daisuke Yabe

  83. Alcohol‐induced impaired insulin secretion in a Japanese population: 5‐year follow up in the Gifu Diabetes Study

    Article • Journal of Diabetes Investigation, May 2020, Wiley

    Dr Daisuke Yabe

  84. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

    Article • The Lancet Diabetes & Endocrinology, May 2020, Elsevier

    Dr Daisuke Yabe

  85. Utility of microcatheter in adrenal venous sampling for primary aldosteronism

    Article • British Journal of Radiology, February 2020, Oxford University Press (OUP)

    Dr Daisuke Yabe

  86. Factory-calibrated continuous glucose monitoring and capillary blood glucose monitoring in a case with insulinoma: usefulness and possible pitfall under chronic hyperinsulinemic hypoglycemia

    Article • Endocrine Journal, January 2020, Japan Endocrine Society

    Dr Daisuke Yabe

  87. Dietary instructions focusing on meal-sequence and nutritional balance for prediabetes subjects: An exploratory, cluster-randomized, prospective, open-label, clinical trial

    Article • Journal of Diabetes and its Complications, December 2019, Elsevier

    Dr Daisuke Yabe

  88. Ceritinib‐associated hyperglycemia in the Japanese Adverse Drug Event Report Database

    Article • Journal of Diabetes Investigation, November 2019, Wiley

    Dr Daisuke Yabe

  89. Low-carbohydrate diet by staple change attenuates postprandial GIP and CPR levels in type 2 diabetes patients

    Article • Journal of Diabetes and its Complications, November 2019, Elsevier

    Dr Daisuke Yabe

  90. GPR40 activation initiates store-operated Ca2+ entry and potentiates insulin secretion via the IP3R1/STIM1/Orai1 pathway in pancreatic β-cells

    Article • Scientific Reports, October 2019, Springer Science + Business Media

    Dr Daisuke Yabe

  91. Dietary recommendations for type 2 diabetes patients: Lessons from recent clinical and basic research in Asia

    Article • Journal of Diabetes Investigation, September 2019, Wiley

    Dr Daisuke Yabe

  92. Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report

    Article • Journal of Diabetes Investigation, September 2019, Wiley

    Dr Daisuke Yabe

  93. The journey to understanding incretin systems: Theory, practice and more theory

    Article • Journal of Diabetes Investigation, August 2019, Wiley

    Dr Daisuke Yabe

  94. Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology

    Article • Journal of Diabetes Investigation, May 2019, Wiley

    Dr Daisuke Yabe

  95. A rare case of autoimmune polyglandular syndrome with Sjögren’s syndrome and primary hypoparathyroidism

    Article • BMJ Case Reports, May 2019, BMJ

    Dr Daisuke Yabe

  96. Sphingosine kinase 1–interacting protein is a dual regulator of insulin and incretin secretion

    Article • The FASEB Journal, February 2019, Wiley

    Shin-ichi Harashima, YANYAN LIU, Daisuke Tanaka, Dr Daisuke Yabe

  97. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity

    Article • Journal of Diabetes Investigation, February 2019, Wiley

    Dr Daisuke Yabe

  98. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials

    Article • Journal of Diabetes Investigation, September 2018, Wiley

    Dr Daisuke Yabe

  99. Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after init

    Article • Journal of Diabetes Investigation, July 2018, Wiley

    Dr Daisuke Yabe

  100. Mental distress and health-related quality of life among type 1 and type 2 diabetes patients using self-monitoring of blood glucose: A cross-sectional questionnaire study in Japan

    Article • Journal of Diabetes Investigation, April 2018, Wiley

    Professor Takeshi Kurose, Dr Daisuke Yabe

  101. Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes

    Article • Journal of Diabetes Investigation, December 2017, Wiley

    Dr Daisuke Yabe

  102. Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation

    Article • Journal of Diabetes Investigation, December 2017, Wiley

    Dr Daisuke Yabe

  103. Beta-cell replacement strategies for diabetes

    Article • Journal of Diabetes Investigation, December 2017, Wiley

    Dr Daisuke Yabe

  104. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes

    Article • Diabetes Obesity and Metabolism, October 2017, Wiley

    Dr Daisuke Yabe

  105. Incretin concept revised: The origin of the insulinotropic function of glucagon-like peptide-1 - the gut, the islets or both?

    Article • Journal of Diabetes Investigation, September 2017, Wiley

    Dr Daisuke Yabe

  106. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation

    Article • Expert Opinion on Drug Safety, August 2017, Taylor & Francis

    Dr Daisuke Yabe

  107. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, singl

    Article • Journal of Diabetes Investigation, July 2017, Wiley

    Dr Daisuke Yabe

  108. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases

    Article • Journal of Diabetes Investigation, June 2017, Wiley

    Dr Daisuke Yabe

  109. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial)

    Article • Diabetes Obesity and Metabolism, April 2017, Wiley

    Dr Daisuke Yabe

  110. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study

    Article • Diabetes Obesity and Metabolism, February 2017, Wiley

    Dr Daisuke Yabe

  111. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial

    Article • Diabetes Obesity and Metabolism, November 2016, Wiley

    Dr Daisuke Yabe

  112. Cardiovascular safety trials of incretin-based drugs: What do they mean?

    Article • Journal of Diabetes Investigation, October 2016, Wiley

    Dr Daisuke Yabe

  113. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials

    Article • Journal of Diabetes and its Complications, September 2016, Elsevier

    Dr Daisuke Yabe

  114. Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin

    Article • Diabetologia, April 2016, Springer Science + Business Media

    Dr Daisuke Yabe

  115. Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives

    Article • Journal of Diabetes Investigation, April 2016, Wiley

    Dr Daisuke Yabe

  116. Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation

    Article • Expert Opinion on Drug Safety, February 2016, Informa Healthcare

    Dr Daisuke Yabe

  117. Type 2 diabetes via β-cell dysfunction in east Asian people

    Article • The Lancet Diabetes & Endocrinology, January 2016, Elsevier

    Dr Daisuke Yabe

  118. Insulin Secretory Defect and Insulin Resistance in Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance

    Article • Journal of Diabetes Research, January 2016, Hindawi Publishing Corporation

    Dr Daisuke Yabe

  119. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial

    Article • Diabetologia, December 2015, Springer Science + Business Media

    Dr Daisuke Yabe

  120. Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan

    Article • Journal of Diabetes and its Complications, November 2015, Elsevier

    Dr Daisuke Yabe

  121. Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation

    Article • Journal of Diabetes and its Complications, November 2015, Elsevier

    Dr Daisuke Yabe

  122. Evidence-based practice guideline for the treatment for diabetes in Japan 2013

    Article • Diabetology International, July 2015, Springer Science + Business Media

    Dr Daisuke Yabe

  123. Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study

    Article • Hormone and Metabolic Research, June 2015, Thieme Publishing Group

    Dr Daisuke Yabe

  124. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points

    Article • Current Medical Research and Opinion, May 2015, Informa Healthcare

    Professor Takeshi Kurose, Dr Daisuke Yabe

  125. β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians

    Article • Current Diabetes Reports, May 2015, Springer Science + Business Media

    Dr Daisuke Yabe

  126. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events

    Article • Expert Opinion on Drug Safety, April 2015, Informa Healthcare

    Dr Daisuke Yabe

  127. A case of hypoglycemia due to illegitimate sexual enhancement medication

    Article • Diabetes Research and Clinical Practice, April 2015, Elsevier

    Professor Takeshi Kurose, Dr Daisuke Yabe

  128. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients

    Article • Journal of Diabetes and its Complications, April 2015, Elsevier

    Dr Daisuke Yabe

  129. A case of insulinoma with non-alcoholic fatty liver disease: Roles of hyperphagia and hyperinsulinemia in pathogenesis of the disease

    Article • Endocrine Journal, January 2015, Japan Endocrine Society

    Dr Daisuke Yabe, Professor Takeshi Kurose

  130. Alogliptin for the treatment of Type 2 diabetes

    Article • Expert Review of Endocrinology & Metabolism, October 2014, Taylor & Francis

    Dr Daisuke Yabe

  131. Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of G et G oal‐ S

    Article • Journal of Diabetes Investigation, September 2014, Wiley

    Dr Daisuke Yabe

  132. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP ‐4 inhibitors with other oral antidiabetic drugs

    Article • Diabetes Obesity and Metabolism, September 2014, Wiley

    Dr Daisuke Yabe

  133. Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes

    Article • Expert Review of Endocrinology & Metabolism, September 2014, Taylor & Francis

    Dr Daisuke Yabe

  134. Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus

    Article • Diabetes Research and Clinical Practice, September 2014, Elsevier

    Dr William D Strain, Dr Daisuke Yabe

  135. The role of chronobiology and circadian rhythms in type 2 diabetes mellitus: implications for management of diabetes

    Article • ChronoPhysiology and Therapy, July 2014, Dove Medical Press

    Dr Daisuke Yabe, Professor Takeshi Kurose

  136. Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?

    Article • Journal of Diabetes Investigation, May 2014, Wiley

    Dr Daisuke Yabe

  137. Relationship and factors responsible for regulating fasting and post‐challenge plasma glucose levels in the early stage development of type 2 diabetes mellitus

    Article • Journal of Diabetes Investigation, May 2014, Wiley

    Dr Daisuke Yabe, Professor Takeshi Kurose

  138. Alogliptin benzoate for the treatment of type 2 diabetes

    Article • Expert Opinion on Pharmacotherapy, March 2014, Informa Healthcare

    Dr Daisuke Yabe

  139. Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea

    Article • Journal of Diabetes Investigation, February 2014, Wiley

    Dr Daisuke Yabe, Professor Takeshi Kurose

  140. Circulating TNF Receptor 2 is Closely Associated with the Kidney Function in Non-Diabetic Japanese Subjects

    Article • Journal of Atherosclerosis and Thrombosis, January 2014, Japan Atherosclerosis Society

    Dr Daisuke Yabe

  141. Incretin actions beyond the pancreas: lessons from knockout mice

    Article • Current Opinion in Pharmacology, December 2013, Elsevier

    Dr Daisuke Yabe

  142. Enhanced glucagon-like peptide-1 secretion in a patient with glucagonoma: Implications for glucagon-like peptide-1 secretion from pancreatic α cells in vivo

    Article • Diabetes Research and Clinical Practice, October 2013, Elsevier

    Dr Daisuke Yabe

  143. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function

    Article • Journal of Diabetes Investigation, June 2013, Wiley

    Dr Daisuke Yabe

  144. Improvement of Fasting Plasma Glucose Level After Ingesting Moderate Amount of Dietary Fiber in Japanese Men With Mild Hyperglycemia and Visceral Fat Obesity

    Article • Journal of Dietary Supplements, June 2013, Taylor & Francis

    Dr Daisuke Yabe

  145. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

    Article • Journal of Diabetes Investigation, March 2013, Wiley

    Dr Daisuke Yabe

  146. Circulating TNF receptor 2 is associated with the development of chronic kidney disease in non-obese Japanese patients with type 2 diabetes

    Article • Diabetes Research and Clinical Practice, February 2013, Elsevier

    Dr Daisuke Yabe

  147. Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin

    Article • Diabetes Therapy, November 2012, Springer Science + Business Media

    Dr Daisuke Yabe, Professor Takeshi Kurose

  148. Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations

    Article • Journal of Diabetes Investigation, May 2012, Wiley

    Dr Daisuke Yabe, Professor Takeshi Kurose

  149. Dipeptidyl peptidase-4 inhibitors and prevention of bone fractures: Effects beyond glyemic control

    Article • Journal of Diabetes Investigation, May 2012, Wiley

    Dr Daisuke Yabe

  150. Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels

    Article • Journal of Diabetes Investigation, April 2012, Wiley

    Dr Daisuke Yabe

  151. Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese

    Article • Journal of Diabetes Investigation, February 2012, Wiley

    Dr Daisuke Yabe, Professor Takeshi Kurose

  152. Smoking and adipose tissue inflammation suppress leptin expression in Japanese obese males: Potential mechanism of resistance to weight loss among Japanese obese smokers

    Article • Tobacco Induced Diseases, January 2012, E.U. European Publishing

    Dr Daisuke Yabe

  153. Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation

    Article • Progress in Biophysics and Molecular Biology, November 2011, Elsevier

    Dr Daisuke Yabe

  154. Glucagon-like peptide-1 secretion by direct stimulation of L cells with luminal sugar vs non-nutritive sweetener

    Article • Journal of Diabetes Investigation, September 2011, Wiley

    Dr Daisuke Yabe

  155. Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference

    Article • Clinical Medicine Insights Endocrinology and Diabetes, September 2011, Libertas Academica, Ltd.

    Dr Daisuke Yabe

  156. Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes

    Article • Journal of Diabetes Investigation, July 2011, Wiley

    Dr Daisuke Yabe

  157. Circadian rhythms and diabetes

    Article • Journal of Diabetes Investigation, February 2011, Wiley

    Dr Daisuke Yabe, Professor Takeshi Kurose

  158. Smoking, white blood cell counts, and TNF system activity in Japanese male subjects with normal glucose tolerance

    Article • Tobacco Induced Diseases, January 2011, E.U. European Publishing

    Dr Daisuke Yabe

  159. GIP and GLP-1, the two incretin hormones: Similarities and differences

    Article • Journal of Diabetes Investigation, February 2010, Wiley

    Dr Daisuke Yabe

  160. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

    Article • Journal of Diabetes Investigation, February 2010, Wiley

    Dr Daisuke Yabe

  161. The Role of Family Nutritional Support in Japanese Patients with Type 2 Diabetes Mellitus

    Article • Internal Medicine, January 2010, Japanese Society of Internal Medicine

    Dr Daisuke Yabe, Professor Takeshi Kurose

  162. Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes

    Article • Endocrine Journal, January 2010, Japan Endocrine Society

    Dr Daisuke Yabe

  163. Fibulin-4 conducts proper elastogenesis via interaction with cross-linking enzyme lysyl oxidase

    Article • Proceedings of the National Academy of Sciences, November 2009, Proceedings of the National Academy of Sciences

    Dr Daisuke Yabe

  164. A case of fulminant type 1 diabetes mellitus with exocrine pancreatic insufficiency and enhanced glucagon response to meal ingestion

    Article • Diabetes Research and Clinical Practice, November 2008, Elsevier

    Dr Daisuke Yabe, Professor Takeshi Kurose

  165. Rbp-j regulates expansion of pancreatic epithelial cells and their differentiation into exocrine cells during mouse development

    Article • Developmental Dynamics, October 2007, Wiley

    Dr Daisuke Yabe

  166. Multiple roles of Notch signaling in cochlear development

    Article • Developmental Biology, July 2007, Elsevier

    Dr Daisuke Yabe

  167. Generation of a conditional knockout allele for mammalian Spen protein Mint/SHARP

    Article • genesis, May 2007, Wiley

    Dr Daisuke Yabe

  168. Msx2-interacting nuclear target protein (Mint) deficiency reveals negative regulation of early thymocyte differentiation by Notch/RBP-J signaling

    Article • Proceedings of the National Academy of Sciences, January 2007, Proceedings of the National Academy of Sciences

    Dr Daisuke Yabe

  169. Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice

    Article • Proceedings of the National Academy of Sciences, January 2007, Proceedings of the National Academy of Sciences

    Dr Daisuke Yabe

  170. Notch/Rbp-j signaling prevents premature endocrine and ductal cell differentiation in the pancreas

    Article • Cell Metabolism, January 2006, Elsevier

    Dr Daisuke Yabe

  171. Inhibition of Notch/RBP-J signaling induces hair cell formation in neonate mouse cochleas

    Article • Journal of Molecular Medicine, November 2005, Springer Science + Business Media

    Dr Daisuke Yabe

  172. Insig-dependent Ubiquitination and Degradation of Mammalian 3-Hydroxy-3-methylglutaryl-CoA Reductase Stimulated by Sterols and Geranylgeraniol

    Article • Journal of Biological Chemistry, December 2003, Elsevier

    Dr Daisuke Yabe

  173. Liver-specific mRNA for Insig-2 down-regulated by insulin: Implications for fatty acid synthesis

    Article • Proceedings of the National Academy of Sciences, March 2003, Proceedings of the National Academy of Sciences

    Dr Daisuke Yabe

  174. Three mutations in sterol-sensing domain of SCAP block interaction with insig and render SREBP cleavage insensitive to sterols

    Article • Proceedings of the National Academy of Sciences, December 2002, Proceedings of the National Academy of Sciences

    Dr Daisuke Yabe

  175. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins

    Article • Proceedings of the National Academy of Sciences, September 2002, Proceedings of the National Academy of Sciences

    Dr Daisuke Yabe

  176. Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER

    Article • Proceedings of the National Academy of Sciences, August 2002, Proceedings of the National Academy of Sciences

    Dr Daisuke Yabe

  177. Crucial Step in Cholesterol Homeostasis

    Article • Cell, August 2002, Elsevier

    Dr Daisuke Yabe

  178. Regulated Step in Cholesterol Feedback Localized to Budding of SCAP from ER Membranes

    Article • Cell, August 2000, Elsevier

    Dr Daisuke Yabe

  179. DANCE, a Novel Secreted RGD Protein Expressed in Developing, Atherosclerotic, and Balloon-injured Arteries

    Article • Journal of Biological Chemistry, August 1999, Elsevier

    Dr Daisuke Yabe

  180. Molecular Cloning, Characterization, and Chromosomal Localization of FKBP23, a Novel FK506-Binding Protein with Ca2+-Binding Ability

    Article • Genomics, November 1998, Elsevier

    Dr Daisuke Yabe, Dr Nobuo Kanazawa

  181. Human Calumenin Gene (CALU): cDNA Isolation and Chromosomal Mapping to 7q32

    Article • Genomics, April 1998, Elsevier

    Dr Daisuke Yabe, Dr Nobuo Kanazawa

  182. Genetic Restriction of AIDS Pathogenesis by an SDF-1 Chemokine Gene Variant

    Article • Science, January 1998, American Association for the Advancement of Science

    Dr Daisuke Yabe

  183. Calumenin, a Ca2+-binding Protein Retained in the Endoplasmic Reticulum with a Novel Carboxyl-terminal Sequence, HDEF

    Article • Journal of Biological Chemistry, July 1997, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Nobuo Kanazawa, Dr Daisuke Yabe